Press Releases

Shanghai, China , November 10, 2025 – WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that it has won the “Golden Bull Award for Technological Innovation” in the selection for Listed companies (Hong Kong Stocks). This recognition is attributed to its end-to-end one-stop CRDMO exceptional services, innovation capability of technology platform and sustained growth value in the capital market.

Launched by China Securities Journal in 1999, the Golden Bull Award for Listed Companies is part of the Golden Bull Series Awards. It aims to identify listed companies with outstanding performance, excellent governance, lofty missions and strong social responsibility, and has become one of the most influential awards in China’s capital market. The “Golden Bull Award for Technological Innovation” specifically honors innovative enterprises that have made breakthrough progress in technology research, development, transformation and other aspects, and set benchmarks for industry development.

As an industry-leading CRDMO in bioconjugates, WuXi XDC has built powerful proprietary technologies, including the WuXiDARx™ technology platform, X-LinC technology, as well as WuXiTecan-1 and WuXiTecan-2 payload linker technologies. With the innovative development of the bioconjugates industry, the company continues to empower customers to conduct diverse R&D activities, with a focus on exploring cutting-edge areas such as bispecific ADCs, dual-payload ADCs, RDCs, AOC, DAC, APC, etc. WuXi XDC has successfully delivered multiple complex bioconjugate projects to our global customers. According to its 2025 interim financial report, WuXi XDC’s global customer base has been expanded to 563, and we have supported our customers in submitting nearly 100 IND applications cumulatively. Notably, 13 out of the top 20 global pharmaceutical companies (*ranked by 2024 revenue) have partnered with us in various stages of projects. By revenue, WuXi XDC currently holds over 22% market share globally, maintaining its leadership in the bioconjugate drug CRDMO sector.

This award reflects the capital market’s high recognition of the company’s technological innovation strength, management practices of ESG, sustained growth and industry leadership. Notably, in August this year, WuXi XDC was included in the MSCI China All Share Index, which also demonstrates the capital market’s recognition of its business performance and development prospects. In the future, as a global leading CRDMO in the bioconjugates field, WuXi XDC will continue to focus on providing end-to-end one-stop services to help customers accelerate the technological innovation and development process of bioconjugate drugs, promote ESG excellence, and create greater value for global investors, partners and the industry.

About WuXi XDC

WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from preclinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com

WuXi XDC Contacts

Investor：wuxixdc.ir@wuxibiologics.com

Media：wuxixdc_pr@wuxibiologics.com

BD：wuxixdc_info@wuxibiologics.com